Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Elacestrant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.98 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.98 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 7/20 | 0.37 |
| ▸ | DRD3 | P35462 | 7/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Elacestrant SCHEMBL2636500 | 1.00 | ESR1 (0.98) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| Elacestrant SCHEMBL29580748 | 1.00 | ESR1 (0.98) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| Elacestrant SCHEMBL229432 | 0.99 | ESR1 (1.00) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| Elacestrant SCHEMBL29359701 | 0.99 | ESR1 (1.00) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| Elacestrant SCHEMBL229431 | 0.99 | ESR1 (1.00) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| SCHEMBL227067 | 0.93 | ESR1 (0.89) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| SCHEMBL227068 | 0.93 | ESR1 (0.89) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| SCHEMBL22355580 | 0.93 | ESR1 (0.89) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| SCHEMBL227455 | 0.92 | ESR1 (0.86) | ESR1ESR2CYP26A1ADRA1DADRA1A | |
| SCHEMBL227456 | 0.92 | ESR1 (0.86) | ESR1ESR2CYP26A1ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582617-B2 | Methods for treating cancer | RADIUS PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260007620-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | UNIV DUKE (US) | 2026-01-08 | — | — | US | disclosed |
| US-20250367140-A1 | METHODS FOR TREATING CANCER | RADIUS PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250367141-A1 | METHODS FOR TREATING CANCER | RADIUS PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250319044-A1 | METHODS FOR TREATING CANCER RESISTANT TO CDK4/6 INHIBITORS | RADIUS PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250241875-A1 | METHODS FOR TREATING CANCER IN MODELS HARBORING ESR1 MUTATIONS | RADIUS PHARMACEUTICALS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250205180-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | DUKE UNIVERSITY | 2025-06-26 | — | — | US | disclosed |
| CN-119912339-A | In the ilast group Process for the preparation of intermediates | 浙江天宇药业股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-12263142-B2 | Method of treating cancer using selective estrogen receptor modulators | DUKE UNIVERSITY (US) | 2025-04-01 | — | — | US | disclosed |
| US-12263141-B2 | Methods for treating cancer | RADIUS PHARMACEUTICALS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| EP-3106159-A1 | THERAPEUTIC REGIMENS | Radius Health, Inc. (US) | 2016-12-21 | — | — | EP | disclosed |
| WO-2016176666-A1 | METHODS OF TREATING CANCER | RADIUS HEALTH, INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016176664-A1 | METHODS FOR TREATING CANCER | RADIUS HEALTH, INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2016176665-A1 | METHODS OF TREATING CANCER | RADIUS HEALTH, INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| EP-2568806-B1 | THERAPEUTIC REGIMENS | RADIUS HEALTH INC (US) | 2016-05-11 | — | — | EP | disclosed |
| US-20160022608-A1 | Therapeutic Regimens | RADIUS HEALTH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2015149045-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | DUKE UNIVERSITY (US) | 2015-10-01 | — | — | WO | disclosed |
| EP-2568806-A1 | THERAPEUTIC REGIMENS | Radius Health, Inc. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20130053448-A1 | Therapeutic Regimens | RADIUS HEALTH, INC. | 2013-02-28 | — | — | US | disclosed |
| WO-2011143469-A1 | THERAPEUTIC REGIMENS | RADIUS HEALTH,INC (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367141-A1 | METHODS FOR TREATING CANCER | TP53, RAD1, BRCA1 | ESR1 43/4885ESR2 56/4885CYP26A1 1557/4885 |
| US-20160022608-A1 | Therapeutic Regimens | MCL1, BCL6, IL2 | ESR1 1735/4885ESR2 284/4885CYP26A1 1233/4885 |
| US-20260007620-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | ESRRA, ESRRG, ESRRB | ESR1 21/4885ESR2 4/4885CYP26A1 235/4885 |
| US-12263141-B2 | Methods for treating cancer | TP53, RAD50, RAD1 | ESR1 46/4885ESR2 136/4885CYP26A1 1499/4885 |
| US-20250205180-A1 | METHOD OF TREATING CANCER USING SELECTIVE ESTROGEN RECEPTOR MODULATORS | ESRRG, ESRRB, ESR2 | ESR1 6/4885ESR2 3/4885CYP26A1 66/4885 |
| US-12582617-B2 | Methods for treating cancer | BRCA1, FSHR, RAD1 | ESR1 11/4885ESR2 51/4885CYP26A1 1911/4885 |
| US-20250367140-A1 | METHODS FOR TREATING CANCER | TP53, RAD50, RAD1 | ESR1 46/4885ESR2 136/4885CYP26A1 1499/4885 |
| US-20130053448-A1 | Therapeutic Regimens | MCL1, BCL6, IL2 | ESR1 1735/4885ESR2 284/4885CYP26A1 1233/4885 |
| US-20250319044-A1 | METHODS FOR TREATING CANCER RESISTANT TO CDK4/6 INHIBITORS | CDK4, ESR1, TP53 | ESR1 2/4885ESR2 40/4885CYP26A1 1336/4885 |
| US-20250241875-A1 | METHODS FOR TREATING CANCER IN MODELS HARBORING ESR1 MUTATIONS | ESR1, ESRRG, ESR2 | ESR1 1/4885ESR2 3/4885CYP26A1 508/4885 |
| US-12263142-B2 | Method of treating cancer using selective estrogen receptor modulators | ESRRG, ESRRB, ESR2 | ESR1 6/4885ESR2 3/4885CYP26A1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.